...
首页> 外文期刊>The Pediatric infectious disease journal >Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.
【24h】

Multicenter study to assess safety and efficacy of INH-A21, a donor-selected human staphylococcal immunoglobulin, for prevention of nosocomial infections in very low birth weight infants.

机译:多中心研究评估了INH-A21(一种供体选择的人葡萄球菌免疫球蛋白)在预防超低出生体重婴儿医院感染中的安全性和有效性。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Prophylactic administration of intravenous immunoglobulin has been inconsistent in reducing the risk of sepsis in very low birth weight (VLBW) infants presumably because of varying titers of organism specific IgG antibodies. INH-A21 is an intravenous immunoglobulin from donors with high titers of antistaphylococcal antibodies. This dose-ranging study explored safety and preliminary activity of INH-A21 for prevention of staphylococcal sepsis in VLBW infants. METHODS: This was a multicenter, double blind, group-sequential study. Infants with birth weights 500-1250 g were randomized to receive up to 4 doses of placebo, 250 mg/kg, 500 mg/kg or 750 mg/kg INH-A21. Safety and frequencies of sepsis were compared across treatment groups. RESULTS: All treatment groups had similar mean gestational age, birth weight, Apgar score and maternal use of antibiotics. Randomizations to 250 mg/kg (N = 94) and 500 mg/kg (N = 96) doses were terminated after interim analyses demonstrated a low probability of finding a difference when compared with placebo. Infants randomized to the INH-A21 750 mg/kg group (N = 157) had fewer episodes of Staphylococcus aureus sepsis [relative risk (RR), 0.37; 95% confidence interval (CI), 0.12-1.12; P = 0.14], candidemia (RR 0.34; 95% CI 0.09-1.22; P = 0.09) and mortality (RR 0.64; 95% CI 0.25-1.61; P = 0.27) when compared with the placebo-treated cohort (N = 158). No dose-related trends were observed for adverse events or morbidities associated with prematurity. CONCLUSIONS: INH-A21 750 mg/kg demonstrated potential to reduce sepsis caused by S. aureus, candidemia and mortality in VLBW infants. Although statistical significance was not reached, based on the magnitude of the estimated differences, the efficacy and safety of INH-A21 750 mg/kg should be evaluated in an adequately powered, well-controlled study.
机译:背景:静脉注射免疫球蛋白的预防性给药在降低极低出生体重(VLBW)婴儿败血症的风险方面一直存在不一致的情况,这可能是由于机体特异性IgG抗体效价变化所致。 INH-A21是静脉滴注免疫球蛋白,来自高滴度抗葡萄球菌抗体的供体。这项剂量范围研究探讨了INH-A21预防VLBW婴儿葡萄球菌败血症的安全性和初步活性。方法:这是一项多中心,双盲,小组顺序研究。出生体重为500-1250 g的婴儿随机接受最多4剂安慰剂,分别为250 mg / kg,500 mg / kg或750 mg / kg INH-A21。比较各治疗组的败血症安全性和发生频率。结果:所有治疗组的平均胎龄,出生体重,Apgar评分和母亲使用抗生素的情况均相似。中期分析显示与安慰剂相比,发现差异的可能性很小,因此终止了250 mg / kg(N = 94)和500 mg / kg(N = 96)剂量的随机分组。随机分配到750 mg / kg INH-A21组的婴儿(N = 157)具有较少的金黄色葡萄球菌败血症发作[相对危险度(RR),0.37;每例婴儿的相对危险度]。 95%置信区间(CI)为0.12-1.12; P = 0.14],与安慰剂治疗的队列比较(N = 158),念珠菌血症(RR 0.34; 95%CI 0.09-1.22; P = 0.09)和死亡率(RR 0.64; 95%CI 0.25-1.61; P = 0.27) )。没有观察到与早产有关的不良事件或发病的剂量相关趋势。结论:750 mg / kg INH-A21表现出减少VLBW婴儿由金黄色葡萄球菌,念珠菌血症和死亡率引起的败血症的潜力。尽管未达到统计学显着性,但根据估计差异的大小,应在功能强大且控制良好的研究中评估750 mg / kg INH-A21的疗效和安全性。

著录项

相似文献

  • 外文文献
  • 中文文献
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号